Resistance to mTOR inhibitors is common in cancer cells due to feedback activation of upstream PI3K kinase, furthering the rationale to combine inhibition of PI3K /mTOR with other targeted inhibitors to achieve a more durable blockade of mTOR signaling [92, 93]. Here, MTOR is linked to cancer.